Clinical applications of pharmacogenomics guided warfarin dosing
- 4 February 2011
- journal article
- review article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 33 (1) , 10-19
Abstract
Aim of the Review To assess the state of the literature concerning pharmacogenomic testing in patients requiring vitamin K antagonists, specifically warfarin. Method We conducted a literature search of MEDLINE and International Pharmaceutical Abstracts using the following words: warfarin, pharmacogenetic, and pharmacogenomic. The search results were reviewed by the authors and papers concerning pharmacogenomic testing in warfarin dosing were procured and reviewed. Additionally bibliographies of papers procured were also examined for other studies. The authors focused on clinical trials concerning the use of pharmacogenomic testing in warfarin dosing. Results Although numerous studies have demonstrated that a significant portion of warfarin dosing variability can be explained by genetic polymorphisms, few prospective studies have been conducted that examine the integration of this information in practical dosing situations. Those that have, have shown that using pharmacogenomic information improves initial dosing estimates and decreases the need for frequent clinic visits and laboratory testing. Data showing a reduction in serious bleeding events is sparse. Cost-effectiveness analyses have generally shown a small but positive effect with pharmacogenomic testing in patients receiving warfarin. Conclusion Several studies have shown that pharmacogenomic testing for warfarin dosing is more accurate that other dosing schemes. Pharmacogenomic testing improves time to a therapeutic international normalized ratio while requiring fewer dosing adjustments. Patients who require higher or lower than usual doses seem to benefit the most. The cost-effectiveness of pharmacogenomic testing as well as preventing of outcomes such as bleeding or thrombosis are not yet elucidated. Pharmacists, especially those in a community setting can play a role in this new technology by educating prescribers and patients concerning pharmacogenomic testing, and by developing and using dosing protocols that incorporate its use.Keywords
This publication has 65 references indexed in Scilit:
- Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsBlood, 2010
- Integration of Genetic, Clinical, and INR Data to Refine Warfarin DosingClinical Pharmacology & Therapeutics, 2010
- Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapyBlood Cells, Molecules, and Diseases, 2009
- Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapyBlood, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- The largest prospective warfarin-treated cohort supports genetic forecastingBlood, 2009
- Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patientsJournal of Thrombosis and Haemostasis, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patientsBritish Journal of Clinical Pharmacology, 2007
- Bleeding Complications With Warfarin UseArchives of internal medicine (1960), 2007